Overview
- Investors announced 445 buyouts in 2025, the second-most on record, according to Bain & Company.
- Exit value is expected to reach about $156 billion, helped by a pickup in sponsor-to-sponsor sales after recent lows.
- A surge in deals over $1 billion lifted overall value and helped offset second‑quarter tariff-related slowdowns in North America and Asia-Pacific.
- Asia-Pacific posted a record year, with activity rebalancing toward India, Japan, and South Korea; India led 2024 by volume at 26%.
- Biopharma reached an estimated $80 billion in 2025 with volume projected to exceed 130 deals, while providers, medtech, and healthcare IT also drew increased investment.